Skip to Content
Learn about Aubagio a treatment of Multiple Sclerosis

Peginterferon beta-1a Pregnancy and Breastfeeding Warnings

Peginterferon beta-1a is also known as: Plegridy

Medically reviewed on Dec 8, 2016

Peginterferon beta-1a Pregnancy Warnings

This drug has not been tested for developmental toxicity in pregnant animals. In monkeys given interferon beta by subcutaneous injection every other day in early pregnancy, no teratogenic or adverse effects on fetal development were observed. Abortifacient activity was evident following 3 to 5 doses. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

See references

Peginterferon beta-1a Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

See references

References for pregnancy information

  1. "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.

References for breastfeeding information

  1. "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide